Studies on the structures and antigenic properties of rabies virus glycoprotein analogues produced in yeast cells

Vaccine

Volumn 17, Issue 3, 1999, Pages 205-218

  Sakamoto, Shin Ichi ^a   Ide, Toshio ^a   Tokiyoshi, Sachio ^a   Nakao, Junji ^a   Hamada, Fukusaburo ^a   Yamamoto, Michitaka ^a   Grosby, Jun Alonso ^b   Ni, Yajin ^c   Kawai, Akihiko ^c  

^a Chemo Sero Therapeutic Research Institute   (Japan)

^b STONY BROOK UNIVERSITY   (United States)

^c Grad Sch Pharmaceutical Sci   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EPITOPE; IMMUNOGLOBULIN ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN G; VIRUS GLYCOPROTEIN;

ANTIGENICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; EXPRESSION VECTOR; IMMUNITY; IMMUNOFLUORESCENCE; MOLECULAR WEIGHT; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FOLDING; PROTEIN STRUCTURE; RABIES VIRUS; YEAST;

ANIMALS; ANTIGENS, VIRAL; DETERGENTS; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, VIRAL; GENES, VIRAL; GENETIC VECTORS; GLYCOPROTEINS; GLYCOSYLATION; GUINEA PIGS; IMMUNOBLOTTING; MICE; OCTOXYNOL; RABIES VIRUS; SACCHAROMYCES CEREVISIAE; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0344474534     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00196-0     Document Type: Article

References (46)

1. Meslin F-X, Fishbein DB, Matter HC. Rationale and prospects for rabies elimination in developing countries. In: Rupprecht CE, Dietzschold B, Koprowski H, editors. Lyssaviruses. Curr Topics Microbiol Immunol 1994;187:1-26.
2. Arellano-Sota C. Biology and control of the vampire bat. Rev Infect Dis. 10 (Suppl 4):1988;S615-619.
3. Escobar-Cifentes E. Program for the elimination of urban rabies in Latin America. Rev Infect Dis. 10 (Suppl 4):1988;S689-692.
4. Sureau P. Contribution to rabies prevention. Vaccine. 10:1992;896-899.
5. Tidke R., Prehaud C., Coulon P., Blancou J., Flamand A. Characterization of a double avirulent mutant of rabies virus and its potency as a vaccine, live or inactivated. Vaccine. 5:1987;229-233.
6. Clark H.F. Rabies viruses increase in virulence when propagated in neuroblastoma cell culture. Science. 199:1978;1072-1075.
7. Whetston C.A., Bunn T.O., Emmons R.W., Wiktor T.J. Use of monoclonal antibodies to confirm vaccine-induced rabies in ten dogs, two cats and one fox. J Am Vet Med Assoc. 185:1984;285-288.
8. Wiktor T.J., Gyorgy E., Schulumberger H.D., Sokol F., Koprowski H. Antigenic properties of rabies virus components. Immunol. 110:1973;269-276.
9. Dietzschold B., Wang H., Rupprecht C.E., Celis E., Tollis M., Ertl H., Herber-Katz E., Koprowski H. Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein. Proc Natl Acad Sci USA. 84:1987;9165-9169.
10. Wiktor T.J., Macfarlen R.I., Reagan K.R., Dietzschold B., Curtis P.J., Wunner W.H., Kieny M.-P., Lath R., Lecoco J.-P., Mackett M., Moss B., Koprowski H. Protection from rabies by vaccinia virus recombinant containing the virus glycoprotein gene. Proc Natl Acad Sci USA. 81:1984;7194-7198.
11. Rupprecht C.E., Wiktor T.J., Johnston D.H., Hamir A.N., Dietzschold B., Wunner W.H., Glickman L.T., Koprowski H. Oral immunization and protection of roccon (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc Natl Acad Sci USA. 83:1986;7947-7950.
12. Pastoret P.P., Brochier B. Development of a recombinant vaccinia-rabies vaccine for oral vaccination of foxes against rabies. Devel Biol Standard. 79:1993;105-111.
13. Prevec L., Cmpbel J.B., Christic S.B., Belbeck L., Graham L.F. A recombinant human adenovirus vaccine against rabies. J Infect Dis. 161:1990;27-30.
14. Charlton K.M., Artois M., Prevec L., Campbell J.B., Casey G.A., Wandeler A.I., Armstrong J. Oral rabies vaccination of skunks and foxes with a recombinant human adenovirus vaccine. Arch Virol. 123:1992;169-180.
15. Lathe R.F., Kieny M.P., Schmitt D., Curtis P., Lecocq J.P. M13 bacteriophage vectors for the expression of foreign proteins in Escherichia coli: the rabies glycoprotein. J Mol Appl Genet. 2:1984;331-342.
16. Malek LT, Soostmeyer G, Garvin RT, James E. The rabies glycoprotein gene is expressed in E. coli as a denatured polypep-tide. In: Chanock RM, Lerner RA, editors. Modern Approaches to Vaccines. New York: Cold Spring Harbor Laboratory, 1984. p. 203-8.
17. Yelverton E., Norton S., Obijeski J.F., Goeddel D.V. Rabies virus glycoprotein analogs. Biosynthesis in Escherichia coli. Science. 219:1983;614-620.
18. Xiang Z.Q., Spitalnik S.L., Cheng J., Erikson J., Wojczyk B., Ertl H.C. Immune responses to nucleic acid vaccines to rabies virus. Virology. 209:1995;569-579.
19. Jabbor M.A., Sivasubramanian N., Nayak D.P. Influenza viral (A/WSN/33) haemagglutinin is expressed and glycosylated in the yeast Saccharomyces cerevisiae. Proc Natl Acad Sci USA. 82:1985;2019-2023.
20. Nozaki C., Makizumi K., Kino Y., Nakatake H., Eto T., Mizuno K., Hamada F., Ohtomo N. Expression of herpes virus glycoprotein B gene in yeast. Virus Res. 4:1985;107-113.
21. Ding M., Wen D., Schlesinger J.M., Wertz W.G., Ball A.L. Expression and glycosylation of the respiratory syncytial virus G protein in Saccharomyces cerevisiae. Virology. 159:1987;450-453.
22. Kniskern P.J., Hagopian A., Burke P., Dunn N., Montgomery D.L., Schultz L.D., Schulman C.A., Carty C.E., Maigetter R.Z., Wampler D.E., Lehman E.D., Yamazaki S., Kubek D.J., Emini E.A., Miller W.J., Hurni W.M., Ellis R.W. The application of molecular biology to the development of novel vaccines. Adv Exp Med Biol. 251:1989;83-98.
23. Valenzvela P., Medina A., Rutter J.W., Ammerer G., Hall D.B. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature (London). 298:1982;347-350.
24. Miyanohara A., Toh-e A., Nozaki C., Hanada F., Ohtomo N., Matubara K. Expression of hepatitis B surface antigen gene in yeast. Proc Natl Acad Sci USA. 80:1983;1-5.
25. Miyanohara A., Imamura T., Araki M., Sugahara K., Ohtomo N., Matsubara K. Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: Synthesis of two polypeptides translated from different initiation codons. J Virol. 59:1986;176-180.
26. Yoshida I., Takamizawa A., Fujita H., Mamabe S., Okabe A. Expression of the hepatitis B antigen gene containing the preS2 region in Saccharomyces cerevisiae. Acta Med Okayama. 45:1991;1-10.
27. Sakamoto S., Ide T., Nakatake H., Tokitoshi S., Yamamoto M., Kawai A., Smith J. Studies on the antigenicity and nucleotide sequence of the rabies virus Nishigahara strain, a current seed strain used for dog vaccine production in Japan. Virus Genes. 8:1994;35-46.
28. Bitter G.A., Egan K.M. Expression of heterologous genes in Saccharomyces cerevisiae from vectors utilizing the glyceraldehyde-3-phosphate dehydrogenase gene promoter. Gene. 32:1984;263-274.
29. Cepko C.L., Roberts B.E., Mulligan R.C. Construction and applications of a highly transmissible murine retrovirus shuttle vector. Cell. 37:1984;1053-1062.
30. Takebe T., Seiki M., Fujisawa J., Hoy P., Yokota K., Arai K., Yoshida M., Arai N. SR alfa promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol. 8:1988;466-472.
31. Ito H., Jukuda Y., Murata K., Kimura A. Transformation of intact yeast cells treated with alkali cations. J Bacteriol. 153:1983;163-168.
32. Aust A., Yun S., Suelter C.H. Pyruvate kinase from yeast (Saccharomyces cerevisiae). Methods Enzymol. 42:1975;176-182.
33. Morimoto K., Iwatani Y., Kawai A. Shedding of Gs protein (a soluble from of the viral glycoprotein) by the rabies virus-infected BHK-21 cells. Virology. 195:1993;541-549.
34. Liem H.E., Cardenas F., Tavassoli M., Poh-Fitzpatrick M.B., Muller-Eberhard U. Quantitative determination of hemolobin and cytochemical standing for peroxidase using 3,3′5,5′-tetramethyl-benzidine dihydrochloride, a safe substrate for benzidine. Anal Biochem. 88:1979;388-393.
35. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA. 76:1979;4350-4354.
36. Hawkes R., Niday E., Gordon J. A dot immunobinding assay for monoclonal and other antibodies. Anal Biochem. 119:1982;142-147.
37. Chu G., Hayakawa H., Berg P. Electroporation for the efficient transfection of mammalian cells with DNA. Nucl Acids Res. 15:1987;1311.
38. Davis LG, Dibner MD, Battey JF. Methods in molecular biology. New York: Elsevier, 1986.
39. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with folin phenol reagent. J Biol Chem. 193:1951;265-275.
40. Dietzschold B., Wiktor T.J., Wunner W.H., Varrichis A. Chemical and immunological analysis of the rabies soluble glycoprotein. Virology. 124:1983;330-337.
41. Morimoto K., Kawai A., Mifune K. Comparison of rabies virus G proteins produced by cDNA-transfected animal cells that display either inducible or constitutive expression of the gene. J Gen Virol. 73:1992;335-345.
42. Wen D., Ding M., Schlesinger M.J. Expression of genes encoding vesicular stomatitis and sindbis virus glycoproteins in yeast leads to formation of disulfide-linked oligomers. Virology. 153:1986;150-154.
43. Naito S., Matsumoto S. Identification of cellular action within the rabies virus. Virology. 91:1978;151-163.
44. Kniskern P.J., Hagopian A., Burke P., Schultz L.D., Montogomery D.L., Hurni W.M., Ip C.Y., Schulman C.A., Maigetter R.Z., Wampler D.E., Kubek D., Sitrin R.D., West D.J., Ellis R.W., Miller W.J. Characterization and evaluation of a recombinant hepatitis B vaccine expressed in yeast defective for N-linked hyperglycosylation. Vaccine. 12:1994;1021-1025.
45. Biemans R., Thines D., Rutgers T., De Wilde M., Cabezon T. The large surface protein of hepatitis B virus is retained in the yeast endoplasmic reticulum and provokes its unique enlargement DNA Cell Biol. 10:1991;191-200.
46. Klepfer S.R., Debouck C., Uffelman J., Jacobs P., Bollen A., Jones E.V. Characterization of rabies glycoprotein expressed in yeast. Arch Virol. 128:1993;269-286.